The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The trades of 10k shares showing after hours today at a price of 42p. Possibly would towards sells, however you would have thought the price would have then dropped. If buys, then a good sign.
*since
That’s how I read it comek, the rns describes it as ‘fully human’ . The ceo in the interview seemed to push this point. They had had the drug licence once 2017 so one would assume research was well advanced before the expediting last week.
So we have dropped lower today to pretty much the latest placing price. The main question i have asked myself today is this, would investors have handed over $10m in exchange for shares where there is no gain to be had ? of course they wouldn't, even in normal market conditions, which we are far away from. Raising that amount in the current market takes some doing so they had to have seen to encouraging developments in the pipeline you would have thought.
I am expecting a renewal in interest here tomorrow. News is developing every hour worldwide with cases numbers and sadly deaths both rising. There is so much information and mis information out there regarding covid-19 , one thing is for sure , that it will be with us for a while yet. The world needs medicines/vaccines to help treat and prevent corona. TILS may well have something here, the RNS last week could be the starting point of a very big move, we will have to wait and see.
That’s a decision you must make with the information we have at our disposal. Numerous scenarios could play out here, it could fizzle out, it could go pop. It’s certainly one to watch as it would move quickly on any positivity. Watching Trumps press conference earlier, who would ever have thought that you would here this: from bbc news
‘ The US Health Secretary Alex Azar and health officials can waive certain laws and license requirements, giving more flexibility to healthcare providers’
If you are invested here or are thinking of investing have a watch of this interview from 2 days ago
https://www.youtube.com/watch?v=mn0Uo4hoclE&t=303s
It is clear that TZLS--501 does have some good advantages over its competitors
Well that was an interesting week. Having sat back now and taken in what has happened over the last few days we now sit here at a share price of 60p. We are now firmly in the grips of the outbreak in Europe with the USA following. We spiked upto over 160p on the RNS that TILS is expediting (Basically fast tracking) the development of TZLS-501,
'The Company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in 2017. '
So my interpretation of the above snippet is that TZLS-501 has been with us for a while so they should already have extensive knowledge about its possible uses, hence the RNS.
We have drifted back down sharply since, to be expected I suppose as currently this share will be very largely news driven. The RNS the following day to raise $10m I suppose took advantage of the rise in sentiment, and they stated the that the funds will go towards the fast track clinical development of TZLS-501 and working capital/other corporate purposes.
Covid 19 will be the news focus for a while yet and hopefully TILS will be hard at work testing. Make no mistake we need news for this to move but if we do get news and its positive I wouldn't want to say where the price could stop. There is obvious risk here due to the nature, I hold a position here and will do so until we have a fuller picture. Getting $10m in a raise in this climate would be a big achievement so would have thought they would see the potential here.
Gabriele Cerrone, chairman, added that Tiziana only became aware of the potential of its anti-IL6R mAb at the weekend after people in Naples with lung problems caused by coronavirus started to respond to treatment with Actemra.
“ We are sitting one of best anti-IL6R monoclonal antibodies on the market but had no idea it could be used for Covid-19 complications on the respiratory system as no-one had ever tried it before.”
From the RNS 11th March . 'The Company believes that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signalling by the membrane-bound and soluble IL-6 receptor and the rapid depletion of circulating IL-6 cytokines, a major cause of lung damage, provides TZLS-501 with distinct advantages for treatment of COVID-19'
Placing shares not admitted until 17th March so nothing really changed here. Experienced company here And have had TZLS-501 since 2017 so know this product very well. Any positive initial tests here will provide and interesting insight.
Largest trade ive ever seen in ATM, you would assume that if someone wanted to offload 11.3m in one go the price would be much lower than 2.5 , if it was a buy you would think it would be higher. Very interesting though and in my eyes is a positive, will be looking to add more tomorrow.
Thanks for sharing Floyd. For me that job listing is one of the most positive posts on this BB I have read and it speaks volumes.
Fully downloaded and working great. Looks good, slick, some good new features. Big improvement on V1, ready for a move to a larger user base. Encouraging progress
Scraped together enough for 2500 more shares.
Merry Christmas to all Bushies. Heres to 2020
Quite some volume today, last time it was this high looking at the chart was back in May.
Holdings RNS from Oak Trust, reducing their holding slightly.
Large delayed sell just popped up maybe working that through today? Obviously the reason for the drop.
Nice to see some good volume here this week. The Crux interview here https://www.youtube.com/watch?v=kkTD770mewc
3600 views of the interview in 3 days.
Ok Ken I will have a go, 1440MWh of battery storage would need approx. 7200 mt vanadium even at a low $25 per kg that would cost $180m .
Thanks for the explanation Alfa.